Celsion Announces ThermoDox® HEAT Study Findings to be Reviewed at the 9th Annual World Conference on Interventional Oncology

  Celsion Announces ThermoDox® HEAT Study Findings to be Reviewed at the 9th
Annual World Conference on Interventional Oncology (WCIO) in New York City on
                                 May 16, 2013

PR Newswire

LAWRENCEVILLE, N.J., May 1, 2013

LAWRENCEVILLE, N.J., May 1, 2013 /PRNewswire/ --Celsion Corporation (NASDAQ:
CLSN) announced today that Professor Riccardo Lencioni, MD, FSIR, EBIR, 2013
WCIO Program Chairman and the Director of the Division of Diagnostic Imaging
and Intervention at Pisa University School of Medicine in Italy and Lead
European Principal Investigator for Celsion's Phase III HEAT Study and Ronnie
T.P. Poon, MD, MS, PhD, FRCS(Edin), FACS, Professor of Surgery at the
University of Hong Kong and Lead Asia Pacific Principal Investigator for
Celsion's Phase III HEAT Study will,in conjunction with their scientific
presentations, review the clinical trial results including new emerging
findings from the HEAT Study post hoc analysis at the 9^th Annual Meeting of
the World Conference on Interventional Oncology, which is being held May 16 –
20, 2013 in New York City. The Company recently reported, based on the post
hoc analysis, that ThermoDox® in combination with radiofrequency ablation
(RFA) markedly improved progression free survival (PFS) and overall survival
(OS) in patients who had optimal RFA. Dr. Lencioni's presentation, titled
"Advances in Image-Guided Ablation" will be held Thursday, May 16, 2013 at
11:00 a.m. EDT in Plenary Session: Multidisciplinary State-of-the Art: HCC and
Professor Poon's presentation, titled "Thermally Sensitive Drug Carriers" will
be held Thursday, May 16, 2013 at 4:30 p.m. EDT in Concurrent Session: New
Drugs/New Carriers/New Devices.

Celsion has conducted a comprehensive analysis of the data from the Phase III
HEAT Study of ThermoDox® in hepatocellular carcinoma (HCC) with key principal
investigators, data experts and liver cancer experts including Professors
Lencioni and Poon. This analysis followed the announcement on January 31,
2013, that ThermoDox® in combination with RFA did not meet the Study's primary
endpoint. Emerging data from the HEAT Study post hoc analysis demonstrates
that ThermoDox® markedly improves progression free survival (PFS) and overall
survival (OS) in patients if their lesions undergo RFA for 45 minutes or
more. These findings apply to HCC lesions from both size cohorts of the HEAT
Study (3-5 cm and 5-7 cm) and represent a sizable subgroup of patients.

"The HEAT Study is the largest clinical trial ever conducted in the field of
image-guided ablation of HCC; as such, there is a trove of important data
emerging from this study regarding the use of ThermoDox® in conjunction with
RFA to treat this serious, deadly cancer," said Professor Lencioni. "I am
pleased to introduce this analysis of a large subgroup which may be indicating
a meaningful clinical benefit in both PFS and overall survival at WCIO. The
details of the data will be presented for peer review at upcoming scientific
meetings. It is important to note that the duration of heat from the RFA
procedure appears to be a key factor in a successful clinical outcome when
combined with ThermoDox® as suggested by this analysis. These findings are
consistent with our understanding of how RFA plus ThermoDox® can potentially
offer an important new treatment for this underserved patient population."

About Celsion Corporation

Celsion is dedicated to the development and commercialization of innovative
cancer drugs, including tumor-targeting treatments using focused heat energy
in combination with heat-activated liposomal drug technology. Celsion has
research, license or commercialization agreements with leading institutions,
including the National Institutes of Health, Duke University Medical Center,
University of Hong Kong, the University of Pisa, the UCLA Department of
Medicine, the Kyungpook National University Hospital, the Beijing Cancer
Hospital and the University of Oxford. For more information on Celsion, visit
our website: http://www.celsion.com.

Celsion wishes to inform readers that forward-looking statements in this
release are made pursuant to the "safe harbor" provisions of the Private
Securities Litigation Reform Act of 1995. Readers are cautioned that such
forward-looking statements involve risks and uncertainties including, without
limitation, unforeseen changes in the course of research and development
activities and in clinical trials; the significant expense, time, and risk of
failure of conducting clinical trials; HEAT Study data is subject to further
verification and review by the HEAT Study Data Management Committee; the need
for Celsion to evaluate its future development plans; termination of the
Technology Development Contract or collaboration between Celsion and HISUN at
any time; possible acquisitions or licenses of other technologies, assets or
businesses or the possible failure to make such acquisitions or licenses;
possible actions by customers, suppliers, competitors, regulatory authorities;
and other risks detailed from time to time in the Celsion 's periodic reports
and prospectuses filed with the Securities and Exchange Commission. Celsion
assumes no obligation to update or supplement forward-looking statements that
become untrue because of subsequent events, new information or otherwise.

Investor Contact
Jeffrey W. Church
Sr. Vice President – Corporate
Strategy and Investor Relations
609-482-2455
jchurch@celsion.com

SOURCE Celsion Corporation

Website: http://www.celsion.com
 
Press spacebar to pause and continue. Press esc to stop.